Imatinib

Imatinib Reactions 1704, p192 - 2 Jun 2018 Philadelphia chromosome-negative acute promyelocytic leukaemia: case report A 59-year-old man developed Philadelphia (Ph) chromosome-negative acute promyelocytic leukaemia following treatment with imatinib [route not stated]. The man, who was diagnosed with chronic myeloid leukaemia (CML) at the age of 51 years, had been receiving imatinib 300–400 mg/day [exact dosage not stated]. He had been maintaining complete molecular response since 30 months post the diagnosis of CML. Subsequently, a bone marrow aspirate revealed increased abnormal promyelocytes with azurophilic granules and Auer rods. The results of subsequent fluorescence in situ hybridisation (FISH) test and PCR test were consistent with the diagnosis of Ph-negative APL. The FISH test and PCR test detected PML-RARA; the translocation breakpoint was located in PML intron 6. It was suspected that the Ph-negative APL was due to the administration of imatinib [duration of treatment to reaction onset not stated]. The man was treated with induction chemotherapy with all- trans retinoic acid, followed by one cycle of consolidation therapy, respectively. Following the chemotherapy, the PML- RARA became undetectable by FISH and PCR. The imatinib therapy was discontinued. Author comment: "Here, we describe a case of Ph- negative acute promyelocytic leukemia (APL) observed in a patient who had been in long-term remission for CML and discuss the clinical and molecular characteristics of imatinib- associated Ph-negative secondary myeloid malignancies." Morita K, et al. Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. Annals of Hematology 97: 1105-1109, No. 6, Jun 2018. Available from: URL: https://doi.org/10.1007/s00277-018-3263-3 - Japan 803323256 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Imatinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/imatinib-jMocsJs1sx
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46835-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p192 - 2 Jun 2018 Philadelphia chromosome-negative acute promyelocytic leukaemia: case report A 59-year-old man developed Philadelphia (Ph) chromosome-negative acute promyelocytic leukaemia following treatment with imatinib [route not stated]. The man, who was diagnosed with chronic myeloid leukaemia (CML) at the age of 51 years, had been receiving imatinib 300–400 mg/day [exact dosage not stated]. He had been maintaining complete molecular response since 30 months post the diagnosis of CML. Subsequently, a bone marrow aspirate revealed increased abnormal promyelocytes with azurophilic granules and Auer rods. The results of subsequent fluorescence in situ hybridisation (FISH) test and PCR test were consistent with the diagnosis of Ph-negative APL. The FISH test and PCR test detected PML-RARA; the translocation breakpoint was located in PML intron 6. It was suspected that the Ph-negative APL was due to the administration of imatinib [duration of treatment to reaction onset not stated]. The man was treated with induction chemotherapy with all- trans retinoic acid, followed by one cycle of consolidation therapy, respectively. Following the chemotherapy, the PML- RARA became undetectable by FISH and PCR. The imatinib therapy was discontinued. Author comment: "Here, we describe a case of Ph- negative acute promyelocytic leukemia (APL) observed in a patient who had been in long-term remission for CML and discuss the clinical and molecular characteristics of imatinib- associated Ph-negative secondary myeloid malignancies." Morita K, et al. Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. Annals of Hematology 97: 1105-1109, No. 6, Jun 2018. Available from: URL: https://doi.org/10.1007/s00277-018-3263-3 - Japan 803323256 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off